Marco Quarta | Targeting Ageing: Emerging Therapeutic Strategies | Milan Longevity Summit 2026

*Senolytics: An Update* What if we could selectively remove the cells that help drive ageing? In this session from *Targeting Ageing: Emerging Therapeutic Strategies* at the *Milan Longevity Summit 2026*, *Dr. Marco Quarta* explores one of the most closely watched areas of longevity biotechnology: *senolytics*. Senescent cells accumulate as we age and can release signals that contribute to chronic inflammation, tissue dysfunction, and age-related disease. Senolytic therapies aim to selectively eliminate these dysfunctional cells, potentially restoring healthier tissue environments and improving function. Dr. Quarta examines where the field stands today, from our evolving understanding of cellular senescence to the challenge of translating promising preclinical discoveries into safe and effective human therapies. The presentation offers a look at both the potential and the scientific hurdles behind one of geroscience's most ambitious therapeutic strategies. Dr. Marco Quarta is Founder and Chief Scientific Officer of *Rubedo Life Sciences*, a biotechnology company developing therapies that target pathological cells associated with ageing and chronic disease. A scientist and entrepreneur in regenerative medicine and longevity biotechnology, his work focuses on translating the biology of cellular ageing into new therapeutic approaches. The Milan Longevity Summit brings together global leaders across science, medicine, policy, business, technology and society to rethink the future of health through a *One Health* perspective—recognising that the wellbeing of people, planet and economies is deeply interconnected. *Learn more about the Milan Longevity Summit:* https://www.milanlongevitysummit.org/speakers26/marco-quarta #MilanLongevitySummit #Longevity #OneHealth #MarcoQuarta #Senolytics #CellularSenescence #Geroscience #LongevityBiotech #HealthyAgeing #Healthspan